Tobramycin and antiglaucoma agents as increasing culprits of periorbital allergic contact dermatitis from topical ophthalmic medications: A 24‐year study from Turkey
Contact Dermatitis · 2023
DOI: 10.1111/cod.14309 ↗At a glance
Journal article in Contact Dermatitis, 2023. Written by Esen Özkaya and 2 co-authors. Institution: Istanbul Faculty of Medicine, Department of Dermatology and Venereology, Istanbul University, Istanbul, Turkey. Major MEDLINE topics: Dermatitis, Allergic Contact. Cited 8 times so far (Crossref); 35 references.
Abstract (original language)
Background
Allergic contact dermatitis (ACD) from topical ophthalmic medications (TOMs) poses an additional disease burden to patients who already suffer from eye problems.
Objectives
To investigate the epidemiological/clinical profile of patients with periorbital ACD from TOMs in Turkey. Patients and Methods This was a retrospective, cross‐sectional, single tertiary centre study based on files of 75 patch tested patients with suspected periorbital ACD from TOMs among a total of 2801 consecutively patch tested patients with suspected ACD of any origin between 1996 and 2019.
Results
Periorbital ACD was diagnosed in 25 of 75 (33.3%) patients (female:male = 1.8:1; age range: 6–85 years) with suspected ACD from TOMs showing an overall prevalence of 0.9% (25/2801) among the whole patch test population. Atopy was not present. Tobramycin‐containing TOMs were the most frequent culprits, followed by antiglaucoma preparations. Their frequency increased, whereas no new cases of neomycin‐induced ACD were observed after 2011. Positivities with thimerosal were of unknown clinical relevance, while benzalkonium chloride (BAC) caused ACD in two patients. The diagnosis would be missed in each 20% of patients without performing day (D) 4 and D7 readings and strip‐patch testing. Ten culprits were identified only by testing with patients' own TOMs in eight (32%) patients.
Conclusions
Aminoglycosides, particularly tobramycin, were the leading cause of ACD from TOMs. The frequency of ACD from tobramycin and antiglaucoma medications increased after 2011. BAC was a rare but important allergen. Additional D4 and D7 readings, strip‐patch testing, and testing with patients' own TOMs seem essential when patch testing with eye medications.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Istanbul Faculty of Medicine, Department of Dermatology and Venereology, Istanbul University, Istanbul, Turkey.
- Faculty of Medicine, Department of Dermatology and Venereology, Çanakkale Onsekiz Mart University, Çanakkale, Turkey.
ORCID profiles: Esen Özkaya, Zeynep Keskinkaya, Goncagül Babuna Kobaner
Cite
APA
Özkaya, E., Keskinkaya, Z., & Babuna Kobaner, G. (2023). Tobramycin and antiglaucoma agents as increasing culprits of periorbital allergic contact dermatitis from topical ophthalmic medications: A 24‐year study from Turkey. Contact Dermatitis. https://doi.org/10.1111/cod.14309
Vancouver
Özkaya E, Keskinkaya Z, Babuna Kobaner G. Tobramycin and antiglaucoma agents as increasing culprits of periorbital allergic contact dermatitis from topical ophthalmic medications: A 24‐year study from Turkey. Contact Dermatitis. 2023. doi:10.1111/cod.14309
BibTeX
@article{zkaya2023,
author = {Özkaya, Esen and Keskinkaya, Zeynep and Babuna Kobaner, Goncagül},
title = {Tobramycin and antiglaucoma agents as increasing culprits of periorbital allergic contact dermatitis from topical ophthalmic medications: A 24‐year study from Turkey},
journal = {Contact Dermatitis},
year = {2023},
doi = {10.1111/cod.14309}
}
EUVIMED